Caris Life Sciences Ipo, Caris Life Sciences, Inc. The Irving, …

Caris Life Sciences Ipo, Caris Life Sciences, Inc. The Irving, … Caris Life Sciences (CAI) Form 4 shows 104. 5 million shares priced between $16 and $18. Investors include Perceptive Advisors, CPP Investments and 19 others. 3B. 5M shares at $16-$18 each. The offering includes 23. the company priced 23,529,412 shares in the IPO Caris Life Sciences completed their IPO on June 18, 2025 to list on NASDAQ with ticker CAI. Caris Life Sciences stands out for its broad molecular and AI-driven cancer diagnostics but faces upcoming volatility as the IPO lock-up expires on 15 December 2025. Caris Life Sciences (Caris) announced that it has priced its initial public offering of about 23. 35 … IPO registration, S-1 SEC filing by Caris Life Sciences on 23 May 25, 3:27pm Caris Life Sciences, a precision oncology company, made its public market debut on the Nasdaq under the ticker 'CAI', with shares surging by 33% to open at $28 after its initial … Caris Life Sciences, Inc. 86 billion raised since 2018 and recent FDA-approved product launches, the … Caris Life Sciences Inc. Get stock prices & access to pre-IPO shares in one place at Hiive. , a healthcare company that uses technology to help diagnose and treat cancer, is seeking to raise $423. 8 billion funding round led by Sixth Street Capital. Morgan, Goldman Sachs & Co. Caris Life Sciences Files for 23. Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform … Caris Life Sciences is a next-generation TechBio company and precision medicine pioneer. 's Definitive Proxy Statement (Form DEF 14A) filed after their … Shares of Caris Life Sciences soared in their public debut Wednesday, as investors bought into the company’s business of molecular profiling and drug research using artificial … At the forefront of this transformation is Caris Life Sciences, a pioneering company that recently captured significant attention with its successful initial public offering (IPO). The biotechnology company started trading at $27 each on Wednesday afternoon, a … Caris Life Sciences Inc. The biotech focused on advancing precision medicine through molecular sequencing services … Cancer treatment continues to evolve with the identification of targets and genetic signatures that guide development of therapies addressing those disease-defining markers. 19% (Updated - June 18, 2025 12:30 PM EDT) Caris Life Sciences (CAI) debuted on NYSE at $27 on Wednesday, after pricing its IPO at $21 per share. With a multi-million-dollar IPO on the horizon, investors and analysts alike are taking a close … About Caris Life Sciences Caris Life Sciences ® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing … Caris Life Sciences, a cancer diagnostics and treatment biotech, raised $494 million in its IPO at $21 per share, above its previously planned $19 to $20 per share range. We are selling 23,529,412 shares of our common stock. initial public offering, aiming to raise up to $423. Caris Life Sciences Eyes $5B Valuation with $423M IPO — Precision Oncology Goes Public with 50% Revenue Growth and 6. The news comes less than 2 months after the Irving, TX-based company closed a $168M … Caris Life Sciences bumped up the pricing of its IPO to raise more than $494. Cancer diagnostic firm Caris Life Sciences said on Monday it was targeting a valuation of $5. 83 billion. 66 billion and signaling a growing investor Caris Life Sciences (CAI) said on Monday that it is raising its initial public offering price range to a range between $19 and $20 a share, from the previous range between $16 and $18 per share IRVING, Texas, May 23, 2025 /PRNewswire/ -- Caris Life Sciences ® ("Caris"), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, … Caris Life Sciences plans a $5. 1 million an When is Caris Life Sciences’s IPO? Caris Life Sciences shares are expected to begin trading on Wednesday, June 18, with the offering expected to run through June 20. Caris claims they’re an AI company, but are they really using … Caris Life Sciences (NASDAQ:CAI) is scheduled to make its trading debut on Wednesday on the Nasdaq after the Irving, Texas-based cancer diagnostics company priced its initial public … Cancer diagnostic firm Caris Life Sciences on Monday increased the proposed price range for its initial public offering in the U. 53M Share IPO at $16-$18/sh Author Vlad Schepkov Stock Markets Published 06/09/2025, 07:19 AM Sixth Street-backed Caris Life Sciences targets $5. The oncology-focused precision medicine company disclosed its IPO’s … Sixth Street-backed Caris Life Sciences is targeting a valuation of up to $5. View '. 3 billion. 8M-share preferred conversion & new RSUs; CEO David Halbert now controls 121M shares ahead of IPO. The … Caris Life Sciences made its NASDAQ debut on Wednesday, posting 33% gains during its first day of trading that brought its valuation close to $8 billion — a roughly 55% … Caris Life Sciences has strategically adjusted its initial public offering (IPO) price range, setting it between $19 and $20 per share. CAI's revenue growth is robust David Dean Halbert, Caris Life Sciences chairman, founder and CEO, joins 'Squawk Box' to discuss the company's IPO debut, how the company uses AI technology to help diagnose and treat cancer, Investing. 5 million shares at … Oncologists use Caris Life Sciences’ products to diagnose cancer and plan treatment, including the search for clinical trials to help their patients. The Irving, Texas Caris Life Sciences has filed for an IPO, with a planned value of $424M, at a valuation per share of $16-18. LLC and Citigroup (NYSE: … Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has announced the pricing of its initial public offering … Caris Life Sciences—an Irving-based leader in precision oncology that filed for an initial public offering last month—plans to raise as much as $423. 5M-Test Data Edge Posted on June 15, 2025 at … In 2021, Caris Life Sciences raised $830 million through a $7. , a health-care company that uses technology to help diagnose and treat cancer, is seeking to raise $423. Summary Cancer diagnostics company Caris Life Sciences has announced its plans for an initial public offering (IPO) in the United States, targeting a valuation of up to $5. The cancer diagnostics company launched its IPO roadshow and said that it will offer about BioTech firm Caris Life Sciences filed on Friday its paperwork to go public in the United States. Caris Life Sciences plans to list on the … Caris Life Sciences raised $494. IRVING, Texas, June 17, 2025 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today … Cancer diagnostic firm Caris Life Sciences said on Monday it is targeting a valuation of up to $5. 9B. 5M through its IPO, offering 23. 35 billion AIとゲノム解析を融合したテックバイオ企業、カリス・ライフ・サイエンスがIPOで28％高発進。資金調達額や成長戦略、株価 Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has announced the pricing of its initial … IPOs are back, it seems. 00 and $18. 23B over 9 rounds from 21 investors. Caris Life Sciences raises IPO price range due to high demand from investors, reflecting confidence in company's technology and revenue growth potential in cancer arena. 35 billion valuation in an IPO — 30% less than it was worth in 2021. The successful IPO of Caris Life Sciences makes its founder David Dean Halbert worth an estimated $3. Caris Life Sciences stock analysis 2025. 5 million shares at a range of $16 to $18 a piece in a NASDAQ IPO. 5 million through its IPO. Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions NEW YORK – Caris Life Sciences on Wednesday priced its previously announced initial public offering of 23,529,412 shares of its common stock at a public offering price of $21 per share, for a total of … Caris Life Sciences (CAI) priced its IPO at $21. provides diagnostics and anatomic pathology services. Whitney. Whitney, and Caanan Partners in 1993, and 227 times the original investors’ … Caris Life Sciences, which offers an AI-powered precision medicine platform focused on oncology, announced terms for its IPO on Monday. (NASDAQ:CAI) is one of the best biotech stocks to buy according to Wall Street analysts. Morgan and … Caris Life Sciences shares ended trading at $28 per share on Wednesday, marking a 33% increase from its initial public offering (IPO) price of $21 per share. 53 million shares of its common stock at a public … Caris Life Sciences' shares jumped nearly 29% in their Nasdaq debut on Wednesday, fetching the cancer diagnostic firm a valuation of $7. It develops an unbiased profiling platform for novel target … Caris Life Sciences ® (“Caris”), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that it has filed a … Cancer diagnostic firm Caris Life Sciences on Monday increased the proposed price range for its initial public offering in the U. Caris Life Sciences (CAI) stock is expected to make its trading debut on Wednesday after the company priced its IPO at $21/share. Irving-based Caris Life Sciences Inc. com -- Caris Life Sciences shares started trading at $27 per share on Wednesday, marking a 29% increase from its initial public offering (IPO) price of $21 per share. initial public offering, after raising its proposed price range. The IPO was priced at … IRVING, Texas, May 23, 2025 /PRNewswire/ -- Caris Life Sciences® ("Caris"), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today … Caris Life Sciences, an AI-driven precision oncology company, is targeting a $5. Usearch identified 14 signals for Caris Life Sciences, including: 2 Startup Funding and 12 Partnerships. , and our comprehensive analysis, click "Buy Market Research". 1 million in gross proceeds from the sale of over 23. 8-5. 86 billion raised since 2018 and recent FDA-approved product launches, the … IPO registration, S-1 SEC filing by Caris Life Sciences on 23 May 25, 3:27pm Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised the proposed deal size for its upcoming IPO on Monday. （CAI. According to one summary, this yields a market cap of $4. 5 million shares, marking a significant move in the biotechnology sector. 3 millones de dólares en su IPO en Estados Unidos, con el objetivo de recaudar 423. initial public offering 專注於癌症精准診斷的醫療科技公司Caris Life Sciences Inc. Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has announced the pricing of its initial public offering … Caris Life Sciences on Monday proposed to sell 23. As a … Caris Life Sciences on Monday proposed to sell 23. P. H. Media Library Explore resources including … CAI -0. - Health Care - Renaissance Capital Biotech company Caris Life Sciences filed its paperwork to go public in the U. US）週五（5月23日）向美國證券交易委員會（SEC）提交IPO申請，計劃募資至多3億美元，並在納斯達克全球精選市場上 … Irving-based Caris Life Sciences has filed for an IPO on the Nasdaq, aiming to scale its AI-driven precision oncology platform. 67 billion and … Biotech company Caris Life Sciences filed its paperwork to go public in the U. Irving-based Caris Life Sciences has filed for an IPO on the Nasdaq, aiming to scale its AI-driven precision oncology platform. initial public offering, as the market for new listings rebounds Caris Life Sciences (NASDAQ:CAI) is scheduled to make its trading debut on Wednesday on the Nasdaq after the Irving, Texas-based cancer diagnostics company priced its initial public … Irving-based Caris Life Sciences filed to go public on the Nasdaq and revealed a significant revenue jump between 2023 and 2024. (Reuters) -Caris Life Sciences' shares jumped nearly 29% in their Nasdaq debut on Wednesday, fetching the cancer diagnostic firm a valuation of $7. Caris Life Sciences's valuation in … CARIS LIFE SCIENCES INC SAYS DO NOT CURRENTLY INTEND TO PAY ANY CASH DIVIDENDS ON CAPITAL STOCK FOR FORESEEABLE FUTURE CARIS LIFE … Caris Life Sciences issued a press release today announcing an $830 million growth equity round at a post-money valuation of $7. BofA Securities, J. Cancer-testing company Caris Life Sciences surged in its stock-market debut Wednesday, continuing a run of strong initial public offerings for revenue-making healthcare companies. 5 million shares at $16 to $18 each. CAI Sixth Street has led an $830 million growth equity round for Caris Life Sciences, valuing the Texas-based biotech company at $7. 75% (Updated - June 18, 2025 12:30 PM EDT) Caris Life Sciences (CAI) debuted on NYSE at $27 on Wednesday, after pricing its IPO at $21 per share. After raising nearly $170 million in venture capital fi | Caris recently began rolling out its MI Cancer Seek companion diagnostic test for genomic tumor profiling. The lab enables the company to further develop and launch its blood-based cancer test called Caris Life Sciences, a medicine company that uses molecular science and artificial intelligence to improve cancer care, has stockholders that include Sixth Street and J. 7 billion as it prepares to list … The stock of Caris Life Sciences shined in its Nasdaq debut on Wednesday, pricing its heavily-subscribed initial public offering at $21 per share and putting A flurry of deal-making hasn’t let up as 2025 comes to a close, with Roche subsidiary Genentech getting in on the action and crafting a multi-year cancer collaboration with Caris … Find the latest Caris Life Sciences, Inc. 1 million in its Nasdaq initial public offering, the cancer diagnostic firm said on Tuesday, amid a rebound in the IPO market. The $5. Still, the company remains unprofitable and … One of the latest companies to hit the public market is Caris Life Sciences (CAI). Caris Life Sciences, a leader in AI-powered precision oncology, has raised its IPO price range to $19–$20 per share, aiming for a valuation up to $5. Their latest funding round was of $168M on … Das Biotech-Unternehmen Caris Life Sciences ist an die Börse gegangen. Caris Life Sciences® ("Caris"), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that it has launched the roadshow for its proposed Caris Life Sciences, a pioneer in molecular diagnostics and AI-driven precision oncology, is gearing up to go public. 3rd party Ad. Caris specializes in personalized … Caris Life Sciences, a pioneer in AI-driven precision oncology, is set to debut on the Nasdaq in June 2025, seeking to raise up to $423. Caris Life Sciences is experiencing rapid growth, leveraging AI and molecular science for personalized medicine, but remains deeply unprofitable despite narrowing losses. US）週五（5月23日）向美國證券交易委員會（SEC）提交IPO申請，計劃募資至多3億美元，並在納斯達克全球精選市場上 … Caris Life Sciences Files for 23. Caris Life Sciences, an AI-driven precision oncology company, is targeting a $5. 53 million shares – the number of shares in the … Caris Life Sciences Announces Pricing of Initial Public Offering Caris Life Sciences, a prominent player in patient-centric technology and precision medicine, has recently priced its … Biotech company Caris Life Sciences filed its paperwork to go public in the U. Caris on Monday said it … Caris Life Sciences applies AI and machine learning to patient samples to detect cancer and as a companion diagnostic guiding the use of targeted cancer therapies. the company priced 23,529,412 shares in the IPO BofA Securities, J. 858B over 9 rounds. 5 million. Caris Life Sciences, Inc. 5m by selling 23. 66 billion and signaling a growing investor appetite for new Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the pricing of its initial public offering of Caris Life Sciences uses artificial intelligence and machine learning to analyze oncology data to diagnose and monitor cancer treatments. About … Assess how Caris Life Sciences, Inc. 00, opened at $27. Caris Life Sciences IPO is one of the few bright spots in an otherwise sluggish biotech IPO market. Caris Life … For IPO Boutique's "scale of 1 to 5" BUY rating on Caris Life Sciences, Inc. Pricing its IPO at $21 per share, Caris ended up debuting far above its initial estimates. ’s initial public offering. . 1 million in its initial public offering on the Nasdaq. 53 million shares of its common stock at a public … Caris Life Sciences (CAI) priced its IPO at $21. By the numbers: The offering values … Caris Life Sciences Inc. S. 53 million shares of its common stock at a public offering price of $21. '’s SEC filing list of recent forms filed on behalf of the company, insider activity, and other data such as its news, stock ticker, and alerts on SEC … Caris Life Sciences, a Texas-based cancer testing company, has successfully completed its initial public offering (IPO) on the Nasdaq, raising $494. Caris Life Sciences (CAI) today announced that it has launched the roadshow for its proposed initial public offering of its common stock. 5M in its initial public offering. Caris Life Science, Inc. 5 millones de dólares mediante la … At the forefront of this transformation is Caris Life Sciences, a pioneering company that recently captured significant attention with its successful initial public offering (IPO). 00 per share. Uses AI to customize immunotherapy, potential long-term investment. 5 million through an IPO priced at $16–$18 … Find the latest Caris Life Sciences, Inc. We expect the public offering price to be between $16. 5 million in an initial public offering. View CAI current price, quote, financial & revenue summaries, forecast, earnings transcripts, and news. 6%). , a health care company that uses technology to help diagnose and treat cancer, raised $494 million in a U. 35 billion valuation in its U. Caris Life Sciences, which specialises in the use of artificial intelligence to guide disease diagnosis, treatment selection, and patient monitoring, has raised the target price for its WASHINGTON (dpa-AFX) - Caris Life Sciences (Caris) announced that it has priced its initial public offering of about 23. When is Caris Life Sciences’s IPO? Caris Life Sciences shares are expected to begin trading on Wednesday, June 18, with the offering expected to run through June 20. Im Folgenden erhalten Sie alle wichtigen Informationen rund um den IPO. The IPO was significant … Next-gen AI TechBio company Caris priced IPO at $21. (CAI): Price Bumped Higher, Intersection of Cancer and AI in High Demand 16 Jun 2025 Caris Life Sciences, Inc. Caris has filed a registration statement on Form S-1 with the U. initial public offering, as the market for new listings rebounds Caris Life Sciencesは、高度な分子プロファイリングとAIベースの技術を開発し、高精度腫瘍学を推進するがん診断企業です。 主力製品であるCaris Molecular Intelligence … Caris Life Sciences, an AI-driven precision oncology company, is targeting a $5. The Irving, Texas-based company is now … Caris Life Sciences apunta a una valoración de hasta 5. 1M. According to DNB Bank and Back Bay Life Science Advisors, only 13 healthcare IPOs … Caris Life Sciences has raised a total funding of $1. 50 mid-point. Another biotechnology vendor has listed publicly with Caris Life Sciences raising almost $500m in an initial public offering in June. 53 million shares – the number of shares in the … Pre-IPO trades for Caris Life Sciences will typically involve accredited investors purchasing shares from current shareholders through specialized investment platforms like UpMarket. Usearch discovered 1 location for Caris Life Sciences including locations in … NEW YORK – Caris Life Sciences went public this week with the goals of further expanding its customer base and getting closer to profitability, executives said in an interview after the company's stock … Discover More Events Discover upcoming industry conferences Caris will attend to help expand precision medicine through expert collaboration, education and research. Caris Life Sciences targets raising $423. Caris Life Sciences plans to raise $423. Caris Life Sciences, a cancer diagnostics and treatment biotech, is targeting a nearly $5. Caris Life Sciences, … David Dean Halbert, Caris Life Sciences chairman, founder and CEO, joins 'Squawk Box' to discuss the company's IPO debut, how the company uses AI technology IPO: Caris Life Sciences (CAI) - Offers an AI-powered molecular diagnostics platform focused on oncology. Caris Life Sciences Inc. (Reuters) -Cancer diagnostic firm Caris Life Sciences said on Monday it is targeting a valuation of up to $5. 3 billion valuation in US IPO Stock Markets Published 06/09/2025, 07:27 AM Updated 06/09/2025, 01:22 PM When is Caris Life Sciences’s IPO? Caris Life Sciences shares are expected to begin trading on Wednesday, June 18, with the offering expected to run through June 20. 5 million shares at $21, above the upwardly revised range of $19 to $20. Not an offer or … Caris Life Sciences announced the pricing of its initial public offering of its common stock at a public offering price of $21. Irving, Texas-based firm When AdvancePCS was sold, it returned 31 times its initial public offering (IPO) value, 150 times the venture capital investment made by J. 7B valuation. At the midpoint, the firm would raise $400 million and be valued at $5. Caris plans Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that it has raised $310 million in growth capital. With $1. 53 billion – if priced at the $19. Caris Life Sciences raises IPO price range to $19-$20 per share, aiming for a $5. 3 billion in its U. This was one of the largest life sciences companies yet to go public in a tough year. Securities … Caris partners with biopharma companies, healthcare providers, and academic institutions to enhance cancer diagnostics, therapy selection, and biomarker identification. 00 – $1. The … 專注於癌症精准診斷的醫療科技公司Caris Life Sciences Inc. The Irving, Texas-based company is now … Caris Life Sciences Inc. (CAI) has filed proposed terms to raise approximately $400 million in gross proceeds from the sale of its common stock in an IPO, Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has announced the pricing of its initial … Caris Life Sciences ist ein Krebsdiagnostikunternehmen, das fortschrittliche molekulare Profilierung und KI-basierte Technologien entwickelt, um die Präzisionsonkologie … Caris Life Sciences has raised $1. 00 above the top of its recently increased range – and sold 23. (CAI) stock quote, history, news and other vital information to help you with your stock trading and investing. 1 billion — which … Caris Life Sciences successfully completed its initial public offering on June 20, 2025, raising $494. … Caris Life Sciences (CAI) priced its IPO at $21. Caris Life Sciences's latest funding round was a IPO for $494. initial public offering, as the market for new listings rebounds. 5m by selling … NEW YORK – Caris Life Sciences said late Friday that it has filed a registration statement with the US Securities and Exchange Commission for an initial public offering. Morgan, Goldman Sachs & Co (NYSE: GS). Forge no longer actively tracks this company. Caris priced its IPO this week to raise more than $494. Irving-based Caris Life Sciences has opened a new $45 million liquid biopsy laboratory in Phoenix. They actively develop and deliver innovative solutions to revolutionize healthcare and improve the … Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23. 67 billion in its U. The substantial 29% increase between the IPO price and opening trade reflects significant market appetite for Caris Life Sciences' shares. Cancer testing company Caris Life Sciences has gone public. The Irving, TX-based company plans to … IRVING, Texas, June 17, 2025 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today … At pricing, Caris Life Sciences would have a market cap of $5. The IPO was strong, with On its first day of trading, Caris Life Sciences enjoyed strong public investor demand for its cancer diagnostics and treatment platform, president David Spetzler tells Axios Pro. WASHINGTON (dpa-AFX) - Caris Life Sciences (Caris) announced that it has priced its initial public offering of about 23. Caris Life Sciences enters the public market with a well-established technology foundation, a large dataset, and growing traction in both clinical and pharmaceutical sectors. 1 million in its Nasdaq debut—well over the range it first proposed last week, in the vicinity of $400 million. 12M on June 18, 2025. 5 million when it goes public … Research Caris Life Sciences' (Nasdaq:CAI) fundamentals, past performance, valuation, dividends and more. On December 4, 2025, Caris Life Sciences (NASDAQ:CAI) announced it will … Caris Life Sciences’ impending IPO could mark a significant moment for the biotech sector, indicating robust investor interest in life sciences and innovative healthcare solutions. 5 million shares of common stock at an expected price range of $16 to $18 per share, … Final Analysis: A Once-in-a-Decade Play on AI and Oncology Caris Life Sciences is not just another healthcare IPO—it's a rare convergence of cutting-edge AI, validated liquid biopsy tech, and elite … Sixth Street-backed Caris Life Sciences is targeting a valuation of up to $5. 1 billion — which … Caris Life Sciences develops molecular profiling and AI-driven technologies to support precision medicine in oncology. 35 billion IPO, offering 23. Caris Life Sciences develops molecular profiling and AI-driven technologies to support precision medicine in oncology. About Caris Life Sciences Caris Life Sciences® is a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine through quality and innovation. 35bn through its upcoming IPO on Nasdaq, as the cancer diagnostics firm looks to raise $423. Caris Life Sciences outlined plans for an initial public offering that could give the precision-medicine company a market capitalization topping $5 billion. 53 million shares – the number of shares in the … Caris Life Sciences bumped up the pricing of its IPO to raise more than $494. 00 (+28. …. IRVING, Texas, June 9, 2025 – Caris Life Sciences ® (“Caris”), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that it has launched the roadshow for its … Caris Life Sciences raised $494. on Friday as the stock market shows signs of recovery after tariff shocks. Currently, no public market … Caris Life Sciences shares rose on their first day of trading in their debut on Nasdaq. (CAI) has filed to raise $100 million in an IPO of its Class A common shares, according to SEC S-1 registration information. Das Biotech-Unternehmen Caris Life Sciences ist an die Börse gegangen. … Caris Life Sciences (CAI) said that it is planning to raise about $423. LLC and Citigroup will serve … Caris Life Sciences Inc. This increase from the previous range of $16 … David Dean Halbert, Caris Life Sciences chairman, founder and CEO, joins 'Squawk Box' to discuss the company's IPO debut, how the company uses AI technology to help diagnose and treat cancer, Caris Life Sciences raised about $494 million in its US initial public offering after pricing 23. Caris Life Sciences, a health care and cancer diagnostic company based in Irving, Texas, raised $494. Discover Caris Life Sciences' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. Buy and sell Caris Life Sciences stock. (Ticker: CAI US) is a United States company specializing in AI-based precision medicine and cancer diagnostics. 53M Share IPO at $16-$18/sh Author Vlad Schepkov Stock Markets Published 06/09/2025, 07:19 AM Learn about Caris’ latest news, discover the events Caris will exhibit at, and explore resources including leadership bios, multimedia library, webinars and podcasts in our media library. (NasdaqGS:CAI) stock price, share price history, and explore other investor’s opinions to make your investment decision. Irving, Texas-based firm … Caris Life Sciences has launched its initial public offering, planning to offer more than 23. (CAI): Peeking at the Prospectus of an … Investing. They raised $494MM at an implied valuation of $5. Caris Life Sciences is planning to go public under the ticker CAI, raising over $400 million dollars at a valuation of $5 billion. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the top of its marketed range. Today’s IPO for Caris Life Sciences (CAI) is indicated to open at $30 after pricing at $21. Read more here. Caris Life Sciences (CAI) has filed for 23,529,412 share IPO at $16-$18 per share. Cancer diagnostic firm Caris Life Sciences on Monday raised the proposed price range for its New York initial public offering, targeting a valuation of up to $5. (CAI) has filed proposed terms to raise approximately $400 million in gross proceeds from the sale of its common stock in an IPO, Caris Life Sciences (CAI) today announced that it has launched the roadshow for its proposed initial public offering of its common stock. Caris Life Sciences (NASDAQ: CAI) has filed for 23,529,412 share IPO at $16-$18 per share. 's management team is paid from their Annual Proxy Caris Life Sciences, Inc. The … CAI 1. 5 million shares at $21 each, a dollar above the top of its revised range. CAI Caris Life Sciences Announces Upcoming Initial Public Offering Caris Life Sciences, a prominent player in precision medicine and next-generation AI TechBio, has … This is Caris Life Sciences, Inc. sunovuf bfsr wergv meoh iiasuso tcoyh tmivhubyo stbn sxh tfsfi